Previous 10 | Next 10 |
2023-06-02 09:11:34 ET Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence . The big gain was sparked by the company's research and d...
2023-06-01 13:42:26 ET Shares of Biohaven Ltd. ( NYSE: BHVN ) added ~14% to reach an all-time high on Thursday following three straight sessions of gains, a day after the neuro-pharmaceutical drug developer conducted its R&D Day. The New Haven, Connecticut-based biotech ...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day PR Newswire Submitted a new drug application (NDA) ...
Biohaven to Present R&D Day at Yale School of Management Biohaven to Present R&D Day at Yale School of Management PR Newswire NEW HAVEN, Conn. , May 25, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceu...
2023-05-12 17:19:52 ET Biohaven press release ( NYSE: BHVN ): Q1 Non-GAAP EPS of -$0.98. Cash, cash equivalents and marketable securities as of March 31, 2023 was $392.0 million. For further details see: Biohaven Non-GAAP EPS of -$0.98
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments PR Newswire Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding C...
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy PR Newswire NEW HAVEN, Conn. , April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a glo...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...